Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Efficacy of Everolimus in Patients With HR+/HER2- High Risk Early Stage Breast Cancer

ESMO-Virtual-Plenary-2021-February-1000x250px

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Welcome and introduction of the faculty; Scientific background and context

Rebecca Dent, National Cancer Centre Singapore, Singapore

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Thomas Bachelot, Centre Leon Berard, Lyon, France

Perspectives

Peter Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, UK

Discussion and Q&A

Faculty and online audience (via chat feature)